Algernon Pharmaceuticals has announced the submission of an Investigational New Drug (IND) application of its drug, NP-120 for COVID-19.
The company has submitted the IND with the US FDA for its planned multinational Phase 2b/3 study of its repurposed drug NP-120 (Ifenprodil) for the treatment of patients suffering from COVID-19. The drug - NP-120 – is an N-methyl-d-aspartate (NDMA) receptor glutamate receptor antagonist and an orally delivered small molecule, originally developed by Sanofi and is approved to treat peripheral circulatory disorders.
The clinical trial for the drug - A Randomized Open-Label Phase 2b/3 Study of the Safety and Efficacy o...